News

Johnson & Johnson Q2 Earnings Review: This Is As Safe As Pharma Investing Gets
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
How Nvidia's size is rewriting the market playbook
Listen and subscribe to Stocks In Translation on Apple Podcasts, Spotify, or wherever you find your favorite podcast.Nvidia’s (NVDA) explosive growth is doing more than lifting portfolios - it’s ...
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...